Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

26 Jul 2011 13:01

For filings with the FSA include the annex For filings with issuer exclude the annex TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are Scancell Holdings plc attached:ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments An event changing the breakdown of voting rights Other (please specify): 3. Full name of person(s) subject to the Calculus Capital Limitednotification obligation:iii 4. Full name of shareholder(s) HSBC Global Custody (UK) Limited (if different from 3.):iv 5. Date of the transaction and date on which the threshold is crossed or 26 July 2011reached: v 6. Date on which issuer notified: 26 July 2011 7. Threshold(s) that is/are crossed or 10,11,12,13%reached: vi, vii 8. Notified details: A: Voting rights attached to shares viii, ix Class/type Situation previous Resulting situation after the triggering of to the triggering transaction shares transaction Number Number Number Number of voting % of voting rightsif possible of of of shares rights x using Shares Voting the ISIN Rights Direct Direct xi Indirect Direct Indirect CODE xii Ordinary Shares ISIN: 15,277,780 15,277,780 25,277,780 25,277,780 13.02 % GB00B39J5N63 B: Qualifying Financial Instruments Resulting situation after the triggering transaction Type of Expiration Exercise/ Number of voting % of voting financial date xiii Conversion Period xiv rights that may be rights instrument acquired if the instrument is exercised/ converted. C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi Resulting situation after the triggering transaction Type of Exercise price Expiration Exercise/ Number of voting % of voting financial date xvii Conversion rights instrument rights xix, xx instrument period refers to xviii Nominal Delta Total (A+B+C) Number of voting rights Percentage of voting rights 25,277,780 13.02 %

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

N/A Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease N/Ato hold: 12. Date on which proxy holder will cease to hold N/Avoting rights: 13. Additional information: N/A 14. Contact name: Calculus Capital Limited 15. Contact telephone number: 0207 493 4940

Note: Annex should only be submitted to the FSA not the issuer Annex: Notification of major interests in sharesxxii A: Identity of the persons or legal entity subject to the notification obligation Full name (including legal form of legal entities) Contact address (registered office for legal entities) Phone number & email Other useful information (at least legal representative for legal persons)

B: Identity of the notifier, if applicable Full name Contact address Phone number & email Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation) C: Additional information

For notes on how to complete form TR-1 please see the FSA website.

XLON
Date   Source Headline
20th Nov 20197:00 amRNSNew European Moditope patent allowed for grant
23rd Oct 20197:00 amRNSDirectorate Change
26th Sep 20197:00 amRNSPosters at Cancer Immunotherapy Conference
12th Sep 20193:56 pmRNSResult of AGM
4th Sep 20197:00 amRNSFirst Collaboration Agreement for AvidiMab
20th Aug 20192:23 pmRNSNotice of AGM
20th Aug 20197:00 amRNSFinal Results for the year ended 30 April 2019
19th Aug 20197:00 amRNSUpdate on the SCIB1 Phase 2 clinical trial
7th Aug 20197:00 amRNSNotice of Final Results
1st Jul 20197:00 amRNSH1 2019 Business Update
18th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20197:00 amRNSBoard Appointment
17th Jun 201910:45 amRNSHolding(s) in Company
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:35 pmRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSShare Subscription and Issue of Equity to Vulpes
29th May 201911:05 amRNSSecond Price Monitoring Extn
29th May 201911:00 amRNSPrice Monitoring Extension
20th May 20197:00 amRNSScancell and CRUK provide an update on SCIB2
10th May 20197:00 amRNSClinical Advisory Board and Update on Modi-1
25th Apr 20197:00 amRNSUK approval to start SCIB1 Phase 2 trial
8th Apr 20197:00 amRNSJapan patent for Moditope immunotherapy platform
21st Mar 20197:00 amRNSProfessor Lindy Durrant receives Waldenström award
20th Mar 20197:00 amRNSScancell strengthens IP portfolio
5th Mar 20196:27 pmRNSHolding(s) in Company
4th Mar 20194:40 pmRNSSecond Price Monitoring Extn
4th Mar 20194:35 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSChange of Auditor
31st Jan 20197:00 amRNSInterim Results
23rd Jan 20197:00 amRNSUpdate on Cancer Research UK's Grand Challenge
21st Jan 20197:00 amRNSAppoints Heads of Research and Manufacturing
12th Nov 20187:00 amRNSScancell to Present at Two Conferences
1st Nov 20187:00 amRNSScancell to present at Proactive Investors Forum
30th Oct 20185:18 pmRNSResults of AGM
30th Oct 20187:00 amRNSIdentification of 2nd Moditope Cancer Vaccine
24th Oct 20189:05 amRNSSecond Price Monitoring Extn
24th Oct 20189:00 amRNSPrice Monitoring Extension
24th Oct 20187:00 amRNSUpdate on SCIB1 Phase 2 Clinical Study
5th Oct 20187:00 amRNSNotice of AGM
25th Sep 20187:00 amRNSFinal Results for the year ended 30 April 2018
18th Sep 20187:00 amRNSNotice of Final Results
10th Aug 20187:00 amRNSBoard Change
9th Aug 20187:00 amRNSAgreement
25th Jul 20182:45 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSIssue of Equity
18th Jul 20187:00 amRNSScancell exercises TriGrid commercial option
23rd May 20187:00 amRNSGrant of European patent for Moditope platform
11th May 20181:11 pmRNSHolding(s) in Company
9th May 201810:12 amRNSHolding(s) in Company
8th May 20187:00 amRNSResult of the Open Offer and PDMR Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.